Please use this identifier to cite or link to this item:
Title: Development of antifungal biopharmaceutical dectin1-FC fusion
Authors: Goh, Melody
Keywords: DRNTU::Engineering::Bioengineering
Issue Date: 2018
Abstract: Invasive fungal infections are a neglected category of disease that has a high mortality and implicated in immunocompromised patients. Dectin-1 (CLEC7A) is a type II transmembrane C-type lectin pattern recognition receptor expressed on innate immune cells such as macrophages, monocytes and neutrophils. These cells identify β-glucans via its single C-type lectin-like domain on its extracellular region. It activates by detecting and binding to cell walls of different types of fungal; triggering intracellular responses like phagocytosis and cytokine production. The absence of β-glucans in human cells presents the opportunity to exploit Dectin-1 as therapeutic vehicle to enhance immune response during a fungal infection. This project aims to develop a soluble Dectin-1 immunoglobulin Fc fragment fusion protein as a potential biopharmaceutical against fungal infections and investigate its ability to enhance phagocytic activity in immune cells. His-trap purification column will also be optimized in this project to obtain optimum purification conditions for this protein.
Rights: Nanyang Technological University
Fulltext Permission: restricted
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Student Reports (FYP/IA/PA/PI)

Files in This Item:
File Description SizeFormat 
AY17-18 FYP REPORT - MELODY GOH - U1522682F.pdf
  Restricted Access
5.05 MBAdobe PDFView/Open

Page view(s) 50

checked on Sep 28, 2020

Download(s) 50

checked on Sep 28, 2020

Google ScholarTM


Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.